

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or part of the contents of this announcement.

SHENZHEN HEPA LINK PHARMACEUTICAL GROUP CO., LTD.
 (深圳市海普瑞藥業集團股份有限公司)
 (A joint stock company incorporated in the People's Republic of China with limited liability)
 (Stock code: 9989)

INTERIM RESULTS ANNOUNCEMENT
 FOR THE SIX MONTHS ENDED JUNE 30, 2024

Company (Board)
 Hepalink)

Group, we our us)
 Reporting Period

FINANCIAL HIGHLIGHTS			
	For the six months ended June 30,		
	2024	2023	%
	RMB'000	RMB'000	
Revenue	2,828,657	2,828,657	100.0%
Operating Profit	999,274	999,274	100.0%
Operating Profit Margin	35.3%	35.3%	
Net Profit	663,684	663,684	100.0%
Net Profit Margin	23.5%	23.5%	
Net Profit per Share	1.294842	1.294842	100.0%

FINANCIAL HIGHLIGHTS

INTERIM CONDENSED CONSOLIDATED STATEMENT OF PROFIT OR LOSS
 For the six months ended June 30, 2024

	Notes	Six months ended June 30, 2024	
		RMB'000 (unaudited)	RMB'000
REVENUE	4	2,828,657	2
		(1,829,383)	(
Gross profit		999,274	5
	5	406,625	0
		(191,911)	(
		(279,610)	(
		11,446	(
		(15,906)	(
	6	(84,504)	(
		(77,765)	(

INTERIM CONDENSED CONSOLIDATED STATEMENT OF
COMPREHENSIVE INCOME

For the six months ended June 30, 2024

	Six months ended June 30,	
	2024	2023
	RMB'000	RMB'000
	(unaudited)	(unaudited)
PROFIT FOR THE PERIOD	<u>662,836</u>	<u>2</u>
OTHER COMPREHENSIVE INCOME		

INTERIM CONDENSED CONSOLIDATED STATEMENTS OF FINANCIAL POSITION

June 30, 2024

	Notes	June 30, 2024 RMB'000 (unaudited)	RMB'000 (
NON-CURRENT ASSETS			
		2,648,093	2
		203,977	0
		2,336,835	2
		366,955	0
		508,835	1
		606,221	0
		817,111	1
		259,425	0
		117,400	0
		107,022	0
Total non-current assets		<u>7,971,874</u>	<u>8</u>
CURRENT ASSETS			
		6,022,241	6
	11	1,314,094	1
		11,015	0
		648,765	0
		45,653	0
		332,872	4
		548	0
		2,280	0
		21,450	0
		2,202,718	1
Total current assets		<u>10,601,636</u>	<u>0</u>
Total assets		<u>18,573,510</u>	<u>0</u>


INTERIM CONDENSED CONSOLIDATED STATEMENTS OF FINANCIAL POSITION (Continued)

June 30, 2024

	Notes	June 30, 2024 RMB'000 (unaudited)	RMB'000 (
CURRENT LIABILITIES			
	12	378,167	0
			8
		431,825	5
		367,641	0
		2,992,776	3
		186,129	3
		89,937	4
		33,434	3
Total current liabilities		4,479,909	4
NON-CURRENT LIABILITIES			
		1,496,572	1
		28,254	0
		242,464	2
		32,996	3
		10,242	0
		73,650	0
Total non-current liabilities		1,884,178	2
NET CURRENT ASSETS		6,121,727	5
TOTAL ASSETS LESS CURRENT LIABILITIES		14,093,601	4
Net assets		12,209,423	1
SHAREHOLDER EQUITY			
		1,467,296	1
		10,667,729	0
		12,135,025	1
		74,398	3
Total shareholder equity		12,209,423	1

MANAGEMENT DISCUSSION AND ANALYSIS

Overview



Handwritten text, possibly bleed-through from the reverse side of the page.

Handwritten text, possibly bleed-through from the reverse side of the page.

HighTide)

1. 2019年1-6月

Sales

2. 2019年7-12月

Heparin Industrial Chain Business

3. 2019年1-6月

4. 2019年7-12月

5. 2019年1-6月

6. 2019年7-12月

7. 2019年1-6月

8. 2019年7-12月

9. 2019年1-6月

10. 2019年7-12月

11. 2019年1-6月

12. 2019年7-12月

13. 2019年1-6月

1. $\lim_{x \rightarrow \infty} \frac{x^2 - 3x + 2}{x^2 + 1} = 1$
 2. $\lim_{x \rightarrow \infty} \frac{2x^3 + x}{x^3 + 5x^2 + 1} = 2$
 3. $\lim_{x \rightarrow \infty} \frac{x^2 + 2x - 1}{x^2 - 1} = 1$
 4. $\lim_{x \rightarrow \infty} \frac{x^3 + x^2 + x + 1}{x^3 + 2x^2 + x + 1} = 1$
 5. $\lim_{x \rightarrow \infty} \frac{3x^2 + x - 1}{x^2 + 2x + 1} = 3$
 6. $\lim_{x \rightarrow \infty} \frac{x^4 + x^3 + x^2 + x + 1}{x^4 + 2x^3 + x^2 + x + 1} = 1$
 7. $\lim_{x \rightarrow \infty} \frac{x^3 + x^2 + x + 1}{x^3 + 2x^2 + x + 1} = 1$
 8. $\lim_{x \rightarrow \infty} \frac{x^2 + 2x + 1}{x^2 + 1} = 1$
 9. $\lim_{x \rightarrow \infty} \frac{x^2 - 3x + 2}{x^2 + 1} = 1$
 10. $\lim_{x \rightarrow \infty} \frac{x^3 + x^2 + x + 1}{x^3 + 2x^2 + x + 1} = 1$

1. $\lim_{x \rightarrow \infty} \frac{x^2 - 3x + 2}{x^2 + 1} = 1$
 2. $\lim_{x \rightarrow \infty} \frac{2x^3 + x}{x^3 + 5x^2 + 1} = 2$
 3. $\lim_{x \rightarrow \infty} \frac{x^2 + 2x - 1}{x^2 - 1} = 1$
 4. $\lim_{x \rightarrow \infty} \frac{x^3 + x^2 + x + 1}{x^3 + 2x^2 + x + 1} = 1$
 5. $\lim_{x \rightarrow \infty} \frac{3x^2 + x - 1}{x^2 + 2x + 1} = 3$
 6. $\lim_{x \rightarrow \infty} \frac{x^4 + x^3 + x^2 + x + 1}{x^4 + 2x^3 + x^2 + x + 1} = 1$
 7. $\lim_{x \rightarrow \infty} \frac{x^3 + x^2 + x + 1}{x^3 + 2x^2 + x + 1} = 1$
 8. $\lim_{x \rightarrow \infty} \frac{x^2 + 2x + 1}{x^2 + 1} = 1$
 9. $\lim_{x \rightarrow \infty} \frac{x^2 - 3x + 2}{x^2 + 1} = 1$
 10. $\lim_{x \rightarrow \infty} \frac{x^3 + x^2 + x + 1}{x^3 + 2x^2 + x + 1} = 1$

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
82
83
84
85
86
87
88
89
90
91
92
93
94
95
96
97
98
99
100

CDMO Business

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
82
83
84
85
86
87
88
89
90
91
92
93
94
95
96
97
98
99
100

Innovative Drugs and Innovative Business

CTTQ)

Oregovomab

AR-301 (Salvecin)



↑

Aridis)

EMA)

RVX-208 (Apabetalone)



,

H1710

10

11

12

13

14

15

16

17

18

19

Outlook

20

21

22

23

24

25

26

27

28

29

30

31

32

33

34

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
82
83
84
85
86
87
88
89
90
91
92
93
94
95
96
97
98
99
100

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
82
83
84
85
86
87
88
89
90
91
92
93
94
95
96
97
98
99
100

Financial Review
Revenue

For the six months ended June 30,

	2024 sales amount RMB 000 (unaudited)	2024 % of revenue	2023 sales amount RMB 000 (unaudited)	2023 % of revenue	Year-on-year increase/ decrease (%)
Product sales	2,245,298	79.4%	2,118,116	78.8%	(6)
License fees	1,453,516	51.4%	1,453,516	51.4%	(
Other sales	747,599	26.4%	747,599	26.4%	7
Other income	44,183	1.6%	44,183	1.6%	0
Other revenue	560,378	19.8%	560,378	19.8%	4
Other	22,981	0.8%	22,981	0.8%	7
Total	2,828,657	100%	2,707,173	100%	4

Notes:

- (1) License fees
- (2) Other revenue





Finance Costs




Taxation



Profit Attributable to Equity Holders of the Company




Earnings per Share



Liquidity and Financial Resources Treasury Policies



Foreign Currency Risk



Liquidity and Financial Resources



Capital Structure



Pledge of Assets

Contingent Liabilities

Asset-liability Ratio

Interest Rate Risk

Indebtedness

	As at June 30, 2024 RMB'000 (unaudited)	RMB'000
	4,489,348	5
	107,084	8
	<u>4,596,432</u>	<u>5</u>
	(2,280)	(
	<u><u>4,594,152</u></u>	<u><u>5</u></u>

1

↑
✓
✓
✓

1

100
0
3

1

As at
June 30,
2024
RMB'000
(unaudited)

RMB'000
(

2,992,776	3
823,328	2
124,652	0
548,592	5
<hr/>	
4,489,348	5
<hr/> <hr/>	

NOTES TO THE INTERIM CONDENSED CONSOLIDATED FINANCIAL INFORMATION

For the six months ended June 30, 2024

1. Corporate Information

PRC)
Hong Kong Stock Exchange
Group)

2.1 Basis of Preparation

IAS)
IFRSs)
RMB)

3. Operating Segment Information

↙
↘

(↘
 ↙

(↘
 ↙

(↘

	RMB'000	RMB'000	RMB'000	RMB'000	RMB'000
1	1	6	5	6	2
1	1	1	4	1	2
	<u>2</u>	<u>1</u>	<u>9</u>	<u>7</u>	<u>5</u>
					(
					<u>2</u>
	0	3	7	2	1
					(
					0
					(
					(
					(
					(
					(
					(
					(
					<u>(</u>
					<u>0</u>

Geographical information

(a) Revenue from external customers

	For the six months ended June 30,	
	2024	2023
	RMB'000	RMB'000
	(unaudited)	(unaudited)
China	6,678	4
North America	580,353	5
Europe	1,390,708	1
Other regions	187,627	0
	663,291	0
	<u>2,828,657</u>	<u>2</u>

(b) Non-current assets

	As at	
	June 30,	June 30,
	2024	2023
	RMB'000	RMB'000
	(unaudited)	(unaudited)
China	2,825,277	2
North America	3,305,483	3
Europe	157,000	0
Other regions	1,357	0
	<u>6,289,117</u>	<u>6</u>

Information about major customers

1

1

1

1

4. Revenue

Revenue from contracts with customers

(

For the six months ended June 30, 2024 (unaudited)

Segment	Finished dose pharmaceutical products RMB'000	API RMB'000	CDMO RMB'000	Others RMB'000	Total RMB'000
Type of goods or services	1,453,516	747,599		44,183	2,245,298
			560,378		560,378
				22,981	22,981
	1,453,516	747,599	560,378	67,164	2,830,457

	RMB'000	RMB'000	RMB'000	RMB'000	RMB'000
Type of goods or services					
	1,547,336	698,062		44,128	2,289,526
			395,381		395,381
				21,339	21,339
	<u>1,547,336</u>	<u>698,062</u>	<u>395,381</u>	<u>65,467</u>	<u>2,706,246</u>
Timing of revenue recognition					
	1,547,336	698,062		44,128	2,289,526
			133,593	6,682	140,275
			261,788	14,657	276,445
	<u>1,547,336</u>	<u>698,062</u>	<u>395,381</u>	<u>65,467</u>	<u>2,706,246</u>

For the six months ended June 30,
2024

RMB'000 RMB'000
(unaudited) (

22,859 \$
425,851 \$

448,710 \$

Sale of products

CDMO services

FFS)

As at
June 30,
2024
RMB'000 RMB'000
(unaudited) (

355,242 \$

5. Other Income and Gains

For the six months ended June 30,
2024
RMB'000
(unaudited)

Ø
RMB'000
(

Other income

	18,596	4
<input checked="" type="checkbox"/>	1,281	1
<input checked="" type="checkbox"/>	3,003	Ø
	<u>207,876</u>	<u>Ø</u>
	<u>230,756</u>	<u>Ø</u>

Other gains

	(12,134)	Ø
	1,361	Ø
	(96,283)	8
	8,607	(
	(583)	Ø
	272,018	7
	<u>2,883</u>	<u>8</u>
	<u>175,869</u>	<u>Ø</u>
	<u><u>406,625</u></u>	<u><u>Ø</u></u>

* ,
RMB ,
1

* ,
,
,
,
,
,
,
,
,
,

6. Finance Costs

For the six months ended June 30,	
2024	Ø
RMB'000	RMB'000
(unaudited)	(
71,970	Ø
6,796	1
776	2
4,962	Ø
<hr/>	<hr/>
84,504	Ø
<hr/> <hr/>	<hr/> <hr/>

7. Profit before Tax

	For the six months ended June 30,	
	2024	2023
	RMB'000	RMB'000
	(unaudited)	(unaudited)
Operating profit	1,443,136	1,240,711
Finance income	386,247	397,461
Finance expense	(128,038)	(124,144)
Other income	18,686	18,821
Other expense	(27,651)	(27,651)
Share of profit of associates	81,041	90,946
Share of loss of associates	(2,698)	(4,315)
Profit before tax	229,924	317,829
Income tax expense	(52,627)	(53,171)
Income tax credit	(18,596)	(18,596)
Share of income tax credit of associates	84,504	84,504
Share of income tax credit of associates	(12,134)	(12,134)
Share of income tax credit of associates	(1,361)	(1,361)
Share of income tax credit of associates	(8,607)	(8,607)
Share of income tax credit of associates	96,283	96,283
Share of income tax credit of associates	583	(583)
Profit after tax	(272,018)	(272,018)
Profit after tax	(11,446)	(11,446)
Profit after tax	(13,934)	(13,934)

8. Income Tax Expense

,

,

1
2
3

4

5
6

7

For the six months ended June 30,
2024
RMB'000
(unaudited)

0
RMB'000
(

4,776	3
58,720	(
4,525	4
(5,041)	8
<u>62,980</u>	<u>4</u>
50,552	9
(2,020)	3
(6,699)	(
<u>41,833</u>	<u>3</u>
<u><u>104,813</u></u>	<u><u>5</u></u>

9. Dividends

,

,

For the six months ended June 30,
2024
RMB'000
(unaudited)

0
RMB'000
(

<u><u>4</u></u>

10. Earnings per Share Attributable to Ordinary Equity Holders of the Parent

1
2
3
4
5

For the six months ended June 30,
2024 0
RMB'000 RMB'000
(unaudited) (

6
7

663,684 3

For the six months ended June 30,
2024 0
(unaudited) (

8
9
10

1,467,296,204 1

11. Account Receivables

11
12
13

As at
June 30,
2024 1
RMB'000 RMB'000
(unaudited) (

1,342,426 1
2,429 3
(30,761) (

1,314,094 1

As at June 30, 2024 RMB'000 (unaudited)	RMB'000 (
1,009,476	1
304,769	0
7,400	0
23,210	2
<u>1,344,855</u>	<u>1</u>
<u>30,761</u>	<u>0</u>
<u><u>1,314,094</u></u>	<u><u>1</u></u>

As at June 30, 2024 RMB'000 (unaudited)	RMB'000 (
40,039	4
(8,491)	2
(787)	(
<u>30,761</u>	<u>1</u>
<u><u>30,761</u></u>	<u><u>0</u></u>

12. Account Payables

As at June 30, 2024 RMB'000 (unaudited)	100	0
		RMB'000 (
<u>378,167</u>		<u>0</u>

As at June 30, 2024 RMB'000 (unaudited)	100	0
		RMB'000 (
373,914		0
3,276		3
476		4
<u>501</u>		<u>1</u>
<u>378,167</u>		<u>0</u>

13. Share Capital

As at June 30, 2024 RMB'000 (unaudited)	100	0
		RMB'000 (
<u>1,467,296</u>		<u>1</u>

Use of Proceeds from the H Share Listing of the Company

H Share Listing
Net Proceeds

Prospectus
1

Announcement
1

1

2

Significant Investments

3

4

Purchase, Sale or Redemption of Listed Securities

5

6

Material Acquisitions and Disposals of Subsidiaries, Associates and Joint Ventures

7

8

Events after the Reporting Period

9

Employee and Remuneration Policy

10

11

Compliance with the Model Code for Securities Transactions by Directors of Listed Issuers

1
2
3
4
5
6
7
8
9
10
11
12

100

Model Code

Review of Interim Results by the Audit Committee

Audit Committee

13
14
15
16
17
18
19
20
21
22
23
24

Interim Dividends

25
26

Publication of 2024 Interim Results Announcement and Interim Report

27
28
29
30

Appreciation



Shenzhen Hepalink Pharmaceutical Group Co., Ltd.

Li Li
Chairman



As at the date of this announcement, the executive directors of the Company are Mr. Li, Ms. Li Tan, Mr. Shan Yu and Mr. Zhang Ping; and the independent non-executive directors of the Company are Dr. Lu Chuan, Mr. Huang Peng and Mr. Yi Ming.

This announcement contains forward-looking statements relating to the business outlook, estimates of financial performance, forecast business plans and growth strategies of the Group. These forward-looking statements are based on information currently available to the Group and are stated herein on the basis of the outlook at the time of announcement. They are based on certain expectations, assumptions and premises, some of which are subjective or beyond control of the Group. These forward-looking statements may prove to be incorrect and may not be realised in the future. Under these forward-looking statements are a large number of risks and uncertainties. In light of the risks and uncertainties, the inclusion of forward-looking statements in this announcement should not be regarded as representations by the Board or the Company.